Surrogate reads like anecdotal is back in play.
Post# of 148109
Quote:
Surrogate reads like anecdotal is back in play.
In FDA's mind, surrogate is most certainly not anecdotal. Biomarkers need to be validated. In oncology, overall/objective response rate (ORR) is an established surrogate endpoint with duration of response (DOR) supporting.